{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:14:19Z","timestamp":1790273659034,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T00:00:00Z","timestamp":1493856000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00595-017-1527-5","type":"journal-article","created":{"date-parts":[[2017,5,4]],"date-time":"2017-05-04T05:49:43Z","timestamp":1493876983000},"page":"1372-1377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer"],"prefix":"10.1007","volume":"47","author":[{"given":"Taishi","family":"Hata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naotsugu","family":"Haraguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matsuda","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takemasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoh","family":"Taroh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Mizushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Doki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,4]]},"reference":[{"key":"1527_CR1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer Version 2.2017. National Comprehensive Cancer Network. Abstract \n                        https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf\n                        \n                     (2016). Accessed 22 Dec 2016."},{"key":"1527_CR2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2014","unstructured":"Sauer R, Becker H, Hohenberger W, R\u00f6del C, Wittekind C, et al. German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2014;351:1731\u201340.","journal-title":"N Engl J Med."},{"key":"1527_CR3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, Fletkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"1527_CR4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.284.8.1008","volume":"284","author":"C Camma","year":"2000","unstructured":"Camma C, Giunta M, Fiorica F, Pagilaro L, Craxi A, Cottone M. Preoperative radiotherapy for respectable rectal cancer: a meta-analysis. JAMA. 2000;284:1008\u201315.","journal-title":"JAMA"},{"key":"1527_CR5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Dutch Colorectal Cancer Group Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638\u201346.","journal-title":"N Engl J Med"},{"key":"1527_CR6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-lelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114\u201323.","journal-title":"N Engl J Med"},{"key":"1527_CR7","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","volume":"246","author":"KC Peeters","year":"2007","unstructured":"Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6\u00a0years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693\u2013701.","journal-title":"Ann Surg."},{"key":"1527_CR8","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO.2007.14.9898","volume":"26","author":"J Cassidy","year":"2008","unstructured":"Cassidy J, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil\/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006\u201312.","journal-title":"J Clin Oncol."},{"key":"1527_CR9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","volume":"32","author":"D Schrag","year":"2014","unstructured":"Schrag D, Weiser MR, Goodman KA, Gonen M, Hollywood E, Cercek A, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513\u20138.","journal-title":"J Clin Oncol."},{"key":"1527_CR10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00595-015-1236-x","volume":"46","author":"H Katayama","year":"2016","unstructured":"Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Matsuda N, et al. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668\u201385.","journal-title":"Surg Today"},{"key":"1527_CR11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s00595-016-1350-4","volume":"47","author":"H Osawa","year":"2017","unstructured":"Osawa H, Nishimura J, Hiraki M, Takahashi H, Haraguchi N, Hata T, et al. Regeneration of peritoneal mesothelial cells after placement of hyaluronate carboxymethyl-cellulose (Seprafilm\u00ae). Surg Today. 2017;47:130\u20136.","journal-title":"Surg Today"},{"key":"1527_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10147-015-0801-z","volume":"20","author":"T Watanabe","year":"2015","unstructured":"Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207\u201339.","journal-title":"Int J Clin Oncol."},{"key":"1527_CR13","first-page":"1","volume":"27","author":"M Shiga","year":"2017","unstructured":"Shiga M, Maeda H, Oba K, Okamoto K, Namikawa T, Fujisawa K, et al. Safety of laparoscopic surgery for colorectal cancer in patients over 80\u00a0years old: a propensity score matching study. Surg Today. 2017;27:1\u20138.","journal-title":"Surg Today"},{"key":"1527_CR14","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00595-013-0811-2","volume":"44","author":"J Hida","year":"2014","unstructured":"Hida J, Okuno K, Tokoro T. Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer. Surg Today. 2014;44:2227\u201342.","journal-title":"Surg Today"},{"key":"1527_CR15","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO.2004.11.069","volume":"22","author":"J Cassidy","year":"2004","unstructured":"Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22:2084\u201391.","journal-title":"J Clin Oncol"},{"key":"1527_CR16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1200\/JCO.2006.06.1143","volume":"24","author":"HS Hochster","year":"2006","unstructured":"Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin\/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. J Clin Oncol. 2006;24:18.","journal-title":"J Clin Oncol"},{"key":"1527_CR17","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1016\/j.ejca.2006.08.034","volume":"42","author":"AA Martoni","year":"2006","unstructured":"Martoni AA, Pinto C, Fabio FD, Lelli G, Rojas Limpe FL, Gentlile AL, et al. Capecitabine plus oxaliplatin (XELOX) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). Eur J Cancer. 2006;42:3161\u20138.","journal-title":"Eur J Cancer"},{"key":"1527_CR18","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/annonc\/mdj060","volume":"17","author":"P Pfeiffer","year":"2006","unstructured":"Pfeiffer P, Sorbye H, Ehrsson H, Fokstuen T, Mortensen JP, Baltesgard L, et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol. 2006;17:252\u20138.","journal-title":"Ann Oncol"},{"key":"1527_CR19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1200\/JCO.2002.07.087","volume":"20","author":"MM Borner","year":"2002","unstructured":"Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M, et al. Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. J Clin Oncol. 2002;20:1759\u201366.","journal-title":"J Clin Oncol"},{"key":"1527_CR20","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","volume":"19","author":"E Cutsem Van","year":"2001","unstructured":"Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"1527_CR21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/sj.bjc.6601676","volume":"90","author":"E Cutsem Van","year":"2004","unstructured":"Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer. 2004;90:1190\u20137.","journal-title":"Br J Cancer"},{"key":"1527_CR22","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","volume":"19","author":"PM Hoff","year":"2001","unstructured":"Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282\u201392.","journal-title":"J Clin Oncol"},{"key":"1527_CR23","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1056\/NEJMoa043116","volume":"352","author":"C Twelves","year":"2005","unstructured":"Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696\u2013704.","journal-title":"N Engl J Med"},{"key":"1527_CR24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJM199412293312602","volume":"331","author":"PF Mansfield","year":"1994","unstructured":"Mansfield PF, Hohn DC, Fornage BD, Gregurich MA, Ota MD. Complications and failures of subclavian-vein catheterization. N Engl J Med. 1994;331:1735\u20138.","journal-title":"N Engl J Med"},{"key":"1527_CR25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jvir.2009.01.022","volume":"20","author":"WJ Zawacki","year":"2009","unstructured":"Zawacki WJ, Walker TG, DeVasher E, Halpern EF, Waltman AC, Wicky ST, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol. 2009;20:624\u20137.","journal-title":"J Vasc Interv Radiol"},{"key":"1527_CR26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0959-8049(01)00371-9","volume":"38","author":"MM Borner","year":"2002","unstructured":"Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer. 2002;38:349\u201358.","journal-title":"Eur J Cancer"},{"key":"1527_CR27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00595-013-0685-3","volume":"44","author":"F Fujita","year":"2014","unstructured":"Fujita F, Torashima Y, Kuroki T, Eguchi S. Risk factors and predictive factors for anastomotic leakage after resection for colorectal cancer: reappraisal of the literature. Surg Today. 2014;44:1595\u2013602.","journal-title":"Surg Today"},{"key":"1527_CR28","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jjco\/hyt115","volume":"43","author":"K Uehara","year":"2013","unstructured":"Uehara K, Hiramatsu K, Maeda A, Sakamoto E, Inoue M, Kobayashi S, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial. Jpn J Clin Oncol. 2013;43:964\u201371.","journal-title":"Jpn J Clin Oncol"},{"key":"1527_CR29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-014-2417-9","volume":"73","author":"J Hasegawa","year":"2014","unstructured":"Hasegawa J, Nishimura J, Mizushima T, Miyake Y, Kim HM, Takemoto H, et al. Neoadjuvant capecitabine and oxaliplatin(XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol. 2014;73:1079\u201387.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-017-1527-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-017-1527-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-017-1527-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T19:07:49Z","timestamp":1506366469000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-017-1527-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,4]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["1527"],"URL":"https:\/\/doi.org\/10.1007\/s00595-017-1527-5","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,4]]}}}